Skip to main content
SpringerLink
Log in

Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy

  • Conference paper
Progressive Supranuclear Palsy: Diagnosis, Pathology, and Therapy

Part of the book series: Journal of Neural Transmission. Supplementa ((NEURAL SUPPL,volume 42))

Summary

Neurotransmitter receptors and neurotransmitter transporters were studied postmortem in the brains of 9 PSP patients by receptor autoradiography. Densities of dopamine uptake sites and neurotensin receptors were significantly reduced in striatum and substantia nigra consistent with a localization of these binding sites on degenerating dopaminergic nigrostriatal projection neurons. The densities of dopamine D1 receptors were unchanged. Dopamine D2 receptors were unaltered when labeled by [125I]-Iodosulpride or [3H]-CV 205 502, but appeared to be significantly reduced when labeled by [3H]-spiperone. Levels of D2 mRNA were comparable to control levels, suggesting that only subtypes of Dopamine D2-like receptors may be affected in PSP. Serotonin (5-HT) uptake sites and 5-HT receptors were not altered. The density of muscarinic receptors was reduced in striatum, possibly related to a degeneration of cholinergic striatal inter-neurons, but increased in internal globus pallidus. GABAA/BZ receptor binding sites were significantly reduced in both segments of globus pallidus, probably as a consequence of severe degeneration of intrinsic pallidal neurons in PSP. Binding of substance P in striatum tended to be decreased but failed to reach statistical significance. Compared to Parkinson’s disease, the densities of more neurotransmitter receptors were altered in PSP. With the exception of increased muscarinic receptor binding sites in medial globus pallidus, the alterations seen in PSP seem to reflect cell loss rather than functional changes.

*

Abbreviations: C caudate, DA dopamine, GPe globus pallidus externus, GPi globus pallidus internus, HD Huntington’s disease, ISHH in situ hybridization histochemistry, NFT neurofibrillary tangle, NT neurotensin, P putamen, PD Parkinson’s disease, PSP Progressive supranuclear palsy, SN substantia nigra, SNc substantia nigra compacta, SNr substantia nigra reticulata, SP substance P, 5-HT 5-hydroxytryptamine, serotonin

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agid Y, Javoy-Agid F, Ruberg M, Pillon B, Dubois B, Duyckaerts C., Hauw J-J, Baron J-C, Scatton B (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. In: Yahr MD, Bergman KJ (eds) Advances in neurology, vol 45. Raven Press, New York.

    Google Scholar 

  • Behrman S, Carroll JD, Janota I, Matthews WB (1969) Progressive supranuclear palsy. Brain 92: 663–678.

    Article  PubMed  CAS  Google Scholar 

  • Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y (1984) [3H]-spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 99: 167–175.

    Article  PubMed  CAS  Google Scholar 

  • Braak H, Jellinger K, Braak E, Bohl J (1992) Allocortical neurofibrillary changes in progressive supranuclear palsy. Acta Neuropathol 84: 478–483.

    Article  PubMed  CAS  Google Scholar 

  • Charuchinda C, Supavilai P, Karobath M, Palacios JM (1987) Dopamine D2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand. J Neurosci 7: 1352–1360.

    PubMed  CAS  Google Scholar 

  • Chinaglia G, Probst A, Palacios JM (1990) Neurotensin receptors in Parkinson’s disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia. Neuroscience 39: 351–360.

    Article  PubMed  CAS  Google Scholar 

  • Chinaglia G, Alvarez FJ, Probst A, Palacios JM (1992) Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson’s disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]-mazindol. Neuroscience 49: 317–327.

    Article  PubMed  CAS  Google Scholar 

  • Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM (1993) Serotoninergic terminals are differentially affected in Parkinson’s disease and progressive supranuclear palsy: an autoradiographic study with [3H]-citalopram. Neuroscience 54: 691–699.

    Article  PubMed  CAS  Google Scholar 

  • CortĂ©s R, Probst A, Palacios JM (1987) Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: forebrain. Neuroscience 20: 65–107.

    Article  PubMed  Google Scholar 

  • CortĂ©s R, Camps M, Gueye B, Probst A, Palacios JM (1989) Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 483: 30–38.

    Article  PubMed  Google Scholar 

  • D’Amato RJ, Largent BL, Snowman AM, Snyder SH (1987) Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther 242: 364–371.

    CAS  Google Scholar 

  • Dietl MM, Sanchez M, Probst A, Palacios JM (1989) Substance P receptors in the human spinal cord: decrease in amyotrophic lateral sclerosis. Brain Res 483: 39–49.

    Article  PubMed  CAS  Google Scholar 

  • Gerfen CR (1991) Substance P (neurokinin-1) receptor mRNA is selectively expressed in cholinergic neurons in the striatum and basal forebrain. Brain Res 556: 165–170.

    Article  PubMed  CAS  Google Scholar 

  • Golbe LI, Davies PH (1988) Progressive supranuclear palsy. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Urban & Schwarzenberg, Baltimore, pp 121–130.

    Google Scholar 

  • Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fischer JB, Burke-Howie KJ, Bunzow JR, Server AC, Civelli O (1989) Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 86: 9762–9766.

    Article  PubMed  CAS  Google Scholar 

  • Hauw J-J, Verny M, Delaère P, Cervera P, He Y, Duyckaerts C (1990) Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy: basic differences with Alzheimer’s disease. Neurosci Lett 119: 182–186.

    Article  PubMed  CAS  Google Scholar 

  • Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 84: 5976–5980.

    Article  PubMed  CAS  Google Scholar 

  • Hirsch EC, Graybiel AM, Hersh LB, Duyckaerts C, Agid Y (1989) Striosomes and extrastriosomal matrix contain different amounts of immunoreactive choline acetyl-transferase in the human striatum. Neurosci Lett 96: 145–150.

    Article  PubMed  CAS  Google Scholar 

  • Hof PR, Delacourte A, Bouras C (1992) Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: a quantitative analysis of six cases. Acta Neuropathol 84: 45–51.

    Article  PubMed  CAS  Google Scholar 

  • Ishino H, Ikeda H, Otsuki S (1975) Contribution to clinical pathology of progressive supranuclear palsy (subcortical argyrophilic dystrophy). On the distribution of neurofibrillary tangles in the basal ganglia and brain-stem and its clinical significance. J Neurol Sci 24: 471–481.

    Article  PubMed  CAS  Google Scholar 

  • Javitch JA, Strittmatter SM, Snyder SH (1985) Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography. J Neurosci 5: 1513–1521.

    PubMed  CAS  Google Scholar 

  • Jellinger K, Riederer P, Tomonaga M (1980) Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm [Suppl] 16: 111–128.

    Google Scholar 

  • Jellinger K (1988) The pedunculopontine nucleus in Parkinson’s disease, progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 51: 540–543.

    Article  PubMed  CAS  Google Scholar 

  • Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 18: 530–536.

    Article  PubMed  CAS  Google Scholar 

  • Landwehrmeyer B, Mengod G, Palacios JM (1993) Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci 5: 145–153.

    Article  PubMed  CAS  Google Scholar 

  • Maher ER, Lees AJ (1986) The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 36: 1005–1008.

    Article  PubMed  CAS  Google Scholar 

  • Martres M-P, Bouthenet M-L, Sales N, Sokoloff P, Schwartz J-C (1985) Widespread distribution of brain dopamine receptors evidenced with [125I]Iodosulpride, a highly selective ligand. Science 228: 752–755.

    Article  PubMed  CAS  Google Scholar 

  • Mengod G, VilarĂł MT, Landwehrmeyer GB, Martinez-Mir MI, Niznik HB, Sunahara RK, Seeman P, O’Dowd BF, Probst A, Palacios JM (1992) Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain. Neurochem Int 20: 33S–43S.

    Article  PubMed  CAS  Google Scholar 

  • Newman GC (1985) Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 35: 1189–1193.

    Article  PubMed  CAS  Google Scholar 

  • Oberlander C, Blaquière B, Pujol J-F (1986) Distinct functions for dopamine and serotonin in locomotor behavior: evidence using the 5-HT1 agonist RU 24969 in globus pallidus-lesioned rats. Neurosci Lett 67: 113–118.

    Article  PubMed  CAS  Google Scholar 

  • Oyanagi K, Takahashi H, Wakabayashi K, Ikuta F (1991) Large neurons in the neostriatum in Alzheimer’s disease and progressive supranuclear palsy: a topographic, histologic and ultrastructural investigation. Brain Res 544: 221–226.

    Article  PubMed  CAS  Google Scholar 

  • Palacios JM, Niehoff DL, Kuhar MJ (1981) [3H]spiperone binding sites in brain: autoradiographic localization of multiple receptors. Brain Res 213: 277–289.

    Article  PubMed  CAS  Google Scholar 

  • Palacios JM, Landwehrmeyer B, Mengod G (1993) Brain dopamine receptors: characterization, distribution and alteration in disease. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders, 2nd edn. Williams & Wilkins, Baltimore, pp 35–54.

    Google Scholar 

  • Pierot L, Desnos C, Blin J, Raisman R, Scherman D, Javoy-Agid F, Ruberg M, Agid Y (1988) D1 and D2-type dopamine receptors in patients with Parkinson’s disease and progressive supranuclear palsy. J Neurol Sci 86: 291–306.

    Article  PubMed  CAS  Google Scholar 

  • Probst A, Langui D, Lautenschlager C, Ulrich J, Brion JP, Anderton BH (1988) Progressive supranuclear palsy: extensive neuropil threads in addition to neurofibrillary tangles. Very similar antigenicity of subcortical neuronal pathology in progressive supranuclear palsy and Alzheimer’s disease. Acta Neuropathol 77: 61–68.

    Article  PubMed  CAS  Google Scholar 

  • Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, Heureux RL, Hauw J-J, Duyckaerts Ch, Gray F, Morel-Maroger A, Rascol A, Serdaru M, Agid Y (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18: 523–529.

    Article  PubMed  CAS  Google Scholar 

  • Steele JC, Richardson JC, Olzewski J (1964) Progressive supranuclear palsy. Arch Neurol 10: 333–359.

    Article  PubMed  CAS  Google Scholar 

  • Steele JC (1972) Progressive supranuclear palsy. Brain 95: 693–704.

    PubMed  CAS  Google Scholar 

  • Tagliavini F, Pilleri G, Gemignani F, Lechi A (1983) Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy. Acta Neuropathol 61: 157–160.

    Article  PubMed  CAS  Google Scholar 

  • Uhl GR, Snyder SH (1977) Neurotensin receptor binding, regional and subcellular distributions favour transmitter role. Eur J Pharmacol 41: 89–91.

    Article  PubMed  CAS  Google Scholar 

  • VilarĂł MT, Wiederhold KH, Palacios JM, Mengod G (1991) Muscarinic M2 receptor mRNA expression and receptor binding in cholinergic and noncholinergic cells in the rat brain: a correlative study using in situ hybridization and receptor autor-adiography. Neuroscience 47: 367–393.

    Article  Google Scholar 

  • Wamsley JK, Zarbin MA, Birdsall JM, Kuhar MJ (1980) Muscarinic cholinergic receptors: autoradiographic localization of high and low affinity agonist binding sites. Brain Res 200: 1–12.

    Article  PubMed  CAS  Google Scholar 

  • Zezula J, CortĂ©s R, Probst A, Palacios JM (1988) Benzodiazepine receptor sites in the human brain: autoradiographic mapping. Neuroscience 25: 771–795.

    Article  PubMed  CAS  Google Scholar 

  • Zweig RM, Whitehouse PJ, Casanova MF, Walker LC, Jankel WR, Price DL (1987) Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 22: 18–25.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Division of Neuropathology, University of Basel, Basel, Switzerland

    B. Landwehrmeyer

  2. Laboratorios Almirall, S. A., Research Institute, Barcelona, Spain

    Dr. J. M. Palacios

  3. Laboratorios Almirall, Cardoner 68, Barcelona, 08024, Spain

    Dr. J. M. Palacios

Authors
  1. B. Landwehrmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. J. M. Palacios
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurology Service, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain

    E. Tolosa

  2. Neurology Service, Robert Wood Johnson University Hospital, New Brunswick, NJ, USA

    R. Duvoisin

  3. Neurological Tissue Bank, Faculty of Medicine, University of Barcelona, Spain

    F. F. Cruz-Sánchez

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Wien

About this paper

Cite this paper

Landwehrmeyer, B., Palacios, J.M. (1994). Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. In: Tolosa, E., Duvoisin, R., Cruz-Sánchez, F.F. (eds) Progressive Supranuclear Palsy: Diagnosis, Pathology, and Therapy. Journal of Neural Transmission. Supplementa, vol 42. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6641-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6641-3_18

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82541-9

  • Online ISBN: 978-3-7091-6641-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation